Source:http://linkedlifedata.com/resource/pubmed/id/19828704
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
25
|
| pubmed:dateCreated |
2009-12-16
|
| pubmed:abstractText |
The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, chi(2), P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:BuckGeorginaG,
pubmed-author:DeWaldGordonG,
pubmed-author:FerrandoAdolfoA,
pubmed-author:FieldingAdele KAK,
pubmed-author:GoldstoneAnthony HAH,
pubmed-author:KetterlingRhett PRP,
pubmed-author:LazarusHillard MHM,
pubmed-author:LitzowMark RMR,
pubmed-author:LugerSelina MSM,
pubmed-author:MansourMarc RMR,
pubmed-author:MarksDavid IDI,
pubmed-author:McMillanAndrew KAK,
pubmed-author:MoormanAnthony VAV,
pubmed-author:PaiettaElisabeth MEM,
pubmed-author:RichardsSusan MSM,
pubmed-author:RoweJacob MJM,
pubmed-author:TallmanMartin SMS
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
10
|
| pubmed:volume |
114
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5136-45
|
| pubmed:dateRevised |
2011-9-26
|
| pubmed:meshHeading |
pubmed-meshheading:19828704-Adult,
pubmed-meshheading:19828704-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19828704-Cytogenetic Analysis,
pubmed-meshheading:19828704-Female,
pubmed-meshheading:19828704-Fusion Proteins, bcr-abl,
pubmed-meshheading:19828704-Humans,
pubmed-meshheading:19828704-Immunophenotyping,
pubmed-meshheading:19828704-In Situ Hybridization, Fluorescence,
pubmed-meshheading:19828704-Male,
pubmed-meshheading:19828704-Middle Aged,
pubmed-meshheading:19828704-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:19828704-Prospective Studies,
pubmed-meshheading:19828704-Remission Induction,
pubmed-meshheading:19828704-Stem Cell Transplantation,
pubmed-meshheading:19828704-Survival Analysis,
pubmed-meshheading:19828704-T-Lymphocytes,
pubmed-meshheading:19828704-Transplantation, Homologous,
pubmed-meshheading:19828704-Treatment Outcome,
pubmed-meshheading:19828704-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
|
| pubmed:affiliation |
Adult Bone Marrow Transplant Unit, University Hospitals Bristol National Health Service Foundation Trust, Bristol, United Kingdom. David.Marks@ubht.nhs.uk
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|